FinnGen Selects Azenta to Propel Personalized Medicine for Population Health Study
Azenta (Nasdaq: AZTA) has announced its participation in the FinnGen project, a large-scale personalized medicine initiative in Finland. Azenta will provide proteomics profiling for up to 20,000 individuals out of the 500,000 Finnish biobank participants in the study. The company will use Olink's advanced proteomics technology to deliver high-quality protein-level measurements across major biological pathways.
This collaboration with the University of Helsinki aims to integrate proteomics insights with extensive genomic data, potentially leading to a deeper understanding of disease mechanisms, new biomarkers for early detection, and novel therapeutic targets. Azenta's involvement underscores its commitment to advancing healthcare innovation and personalized treatments.
Azenta (Nasdaq: AZTA) ha annunciato la sua partecipazione al progetto FinnGen, un'iniziativa di medicina personalizzata su larga scala in Finlandia. Azenta fornirà profilazione proteomica per un massimo di 20.000 individui su 500.000 partecipanti del biobanco finlandese nello studio. L'azienda utilizzerà la tecnologia avanzata di proteomica di Olink per fornire misurazioni di alta qualità a livello proteico attraverso i principali percorsi biologici.
Questa collaborazione con l'Università di Helsinki mira a integrare le informazioni proteomiche con estesi dati genomici, con l'obiettivo di portare a una comprensione più profonda dei meccanismi di malattia, nuovi biomarcatori per la rilevazione precoce e nuovi target terapeutici. Il coinvolgimento di Azenta sottolinea il suo impegno per l'innovazione nella salute e i trattamenti personalizzati.
Azenta (Nasdaq: AZTA) ha anunciado su participación en el proyecto FinnGen, una iniciativa de medicina personalizada a gran escala en Finlandia. Azenta proporcionará perfilado proteómico para hasta 20,000 individuos de los 500,000 participantes del biobanco finlandés en el estudio. La empresa utilizará la tecnología avanzada de proteómica de Olink para entregar mediciones de alta calidad a nivel de proteínas a través de las principales vías biológicas.
Esta colaboración con la Universidad de Helsinki tiene como objetivo integrar los conocimientos proteómicos con datos genómicos extensos, lo que podría conducir a una comprensión más profunda de los mecanismos de enfermedades, nuevos biomarcadores para la detección temprana y nuevos objetivos terapéuticos. La participación de Azenta subraya su compromiso de avanzar en la innovación en salud y tratamientos personalizados.
Azenta(Nasdaq: AZTA)는 핀란드에서 진행되는 대규모 개인 맞춤형 의학 이니셔티브인 FinnGen 프로젝트에 참여한다고 발표했습니다. Azenta는 연구에 참여하는 50만 핀란드 생물 은행 참여자 중 최대 2만 명의 단백질체 프로파일링을 제공할 예정입니다. 이 회사는 Olink의 고급 단백질체 기술을 사용하여 주요 생물학적 경로에 걸쳐 고품질의 단백질 수준 측정을 제공합니다.
헬싱키 대학교와의 이번 협력은 단백질체 통찰력을 광범위한 유전체 데이터와 통합하는 것을 목표로 하며, 이는 질병 메커니즘에 대한 더 깊은 이해, 조기 발견을 위한 새로운 바이오마커 및 혁신적인 치료 표적을 이끌어낼 수 있습니다. Azenta의 참여는 건강 관리 혁신과 개인 맞춤형 치료에 대한 헌신을 강조합니다.
Azenta (Nasdaq: AZTA) a annoncé sa participation au projet FinnGen, une initiative de médecine personnalisée à grande échelle en Finlande. Azenta fournira profilage protéomique pour jusqu'à 20 000 individus parmi les 500 000 participants du biobanque finlandais à l'étude. L'entreprise utilisera la technologie de protéomique avancée d'Olink pour fournir des mesures de niveau protéique de haute qualité à travers les principales voies biologiques.
Cette collaboration avec l'Université d'Helsinki vise à intégrer les résultats protéomiques avec des données génomiques étendues, ce qui pourrait mener à une compréhension plus approfondie des mécanismes de maladies, à de nouveaux biomarqueurs pour une détection précoce, et à de nouvelles cibles thérapeutiques. L'implication d'Azenta souligne son engagement à faire avancer l'innovation en matière de santé et les traitements personnalisés.
Azenta (Nasdaq: AZTA) hat seine Teilnahme am FinnGen-Projekt angekündigt, einer großangelegten Initiative zur personalisierten Medizin in Finnland. Azenta wird Proteomprofilierung für bis zu 20.000 Personen aus den 500.000 finnischen Biobank-Teilnehmern der Studie bereitstellen. Das Unternehmen wird die fortschrittliche Proteomtechnologie von Olink nutzen, um qualitativ hochwertige Proteinmessungen über wichtige biologische Wege hinweg bereitzustellen.
Diese Zusammenarbeit mit der Universität Helsinki zielt darauf ab, Proteomik-Einblicke mit umfangreichen genomischen Daten zu integrieren, was möglicherweise zu einem tieferen Verständnis von Krankheitsmechanismen, neuen Biomarkern zur frühzeitigen Erkennung und neuen therapeutischen Zielen führen könnte. Die Beteiligung von Azenta unterstreicht das Engagement des Unternehmens für die Förderung von Innovationen im Gesundheitswesen und personalisierten Behandlungen.
- Azenta secures a significant contract to provide proteomics profiling for up to 20,000 individuals in the FinnGen project
- Collaboration with a large-scale research initiative (500,000 participants) enhances Azenta's position in the personalized medicine market
- Utilization of advanced proteomics technology strengthens Azenta's service offerings in the life sciences sector
- None.
Insights
The collaboration between Azenta and the FinnGen project represents a significant step forward in personalized medicine. By leveraging Azenta's advanced proteomics profiling, the FinnGen project can integrate protein-level data with existing genomic data, leading to a more comprehensive understanding of disease mechanisms. This integration can potentially identify new biomarkers for early detection and novel therapeutic targets. The use of Olink's Proximity Extension Assay technology ensures high-quality, reliable measurements, which are important for the accuracy and validity of the research findings. This partnership underscores Azenta's role in pushing the boundaries of healthcare innovation.
This partnership is likely to have a positive impact on Azenta's financial performance. The collaboration with a large-scale, high-profile project like FinnGen enhances Azenta's credibility and positions it as a leader in the field of proteomics. This can lead to increased demand for Azenta's services and potentially open doors to more high-value collaborations. Furthermore, the successful execution of this project could lead to further advancements and innovations in personalized medicine, creating new revenue streams for Azenta. Investors should consider this collaboration as a positive development for the company's future growth prospects.
The adoption of Olink's Proximity Extension Assay technology for this large-scale project highlights its robustness and reliability in producing high-quality proteomics data. This technology allows researchers to measure protein levels across various biological pathways, providing a dynamic and detailed view of the proteome. Such detailed measurements are essential for understanding the complexities of human health and disease at a molecular level. The successful integration of this technology into the FinnGen project not only validates its efficacy but also sets a benchmark for future proteomics studies. This move can significantly influence the adoption of similar technologies in other large-scale health studies, marking a pivotal advancement in the field.
Azenta will provide proteomics technology profiling on up to 20,000 individuals.
In collaboration with the University of
"FinnGen's adoption of proteomics marks a pivotal advancement in our quest to decode the complexities of human health and disease. By integrating the dynamic insights of proteomics with our extensive genomic data, we can gain a deeper understanding of disease mechanisms, identify new biomarkers for early detection, and uncover novel therapeutic targets. We are pleased to collaborate with Azenta Life Sciences, and trust that they will provide excellent service and deliver high-quality proteomic data with a fast turnaround time," said Professor Aarno Palotie, FinnGen Scientific Director from the Institute for Molecular Medicine Finland (FIMM), University of Helsinki. "Combined with excellent quality and reliable results, Azenta Life Sciences can help us construct a strong foundation for advancing the field of personalized medicine."
"As one of the collaborators in the FinnGen Project, Azenta looks forward to making meaningful contributions to personalized medicine and revolutionizing healthcare for generations to come," said Ginger Zhou, PhD., Senior Vice President and General Manager, GENEWIZ Multiomics & Synthesis Solutions from Azenta Life Sciences. "Multiomics technologies from Azenta enable researchers to efficiently generate detailed proteomics data from study participants carrying medically and clinically significant genetic variants, opening up a world of possibilities for understanding disease mechanisms and developing targeted treatments."
About FinnGen
FinnGen is a large public-private partnership aiming to collect and analyze genome and health data from 500,000 Finnish biobank participants. FinnGen aims on one hand to provide novel medically and therapeutically relevant insights but also construct a world-class resource that can be applied for future studies.
FinnGen is one of the very first personalized medicine projects at this scale and the public-private collaborative nature of the project is exceptional compared to many ongoing studies. FinnGen brings together Finnish universities, hospitals and hospital districts, THL, Blood Service, biobanks, FINBB and international pharmaceutical companies and hundreds of thousands of Finns. Because collaboration is the key to achieving breakthroughs in disease prevention, diagnosis, and treatment, we welcome everyone on this journey into our shared heritage.
For more information, please visit https://www.finngen.fi/en.
About Azenta Life Sciences
Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research, and advanced cell therapies for the industry's top pharmaceutical, biotech, academic, and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey and B Medical Systems.
Azenta is headquartered in Burlington,
"Safe Harbor Statement" under Section 21E of the Securities Exchange Act of 1934
Some statements in this release are forward-looking statements made under Section 21E of the Securities Exchange Act of 1934. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Azenta's financial and business results to differ materially from our expectations. They are based on the facts known to management at the time they are made. Other forward-looking statements include but are not limited to statements about the prospects of the FinnGen Project and our ability to contribute to the advancement of personalized medicine. Factors that could cause results to differ from our expectations include the following: changes in technology and/or science that impact our ability to enable researchers to generate the proteomics data required to understand disease and develop targeted treatments and other factors and other risks, including those that we have described in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K, Current Reports on Form 8-K and our Quarterly Reports on Form 10-Q. As a result, we can provide no assurance that our future results will not be materially different from those projected. Azenta expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in our expectations or any change in events, conditions, or circumstances on which any such statement is based. Azenta undertakes no obligation to update the information contained in this press release.
INVESTOR CONTACTS:
Yvonne Perron
Vice President, Financial Planning & Analysis, and Investor Relations
ir@azenta.com
Sherry Dinsmore
sherry.dinsmore@azenta.com
Azenta's use of third-party trademarks and brands are for identification only and does not imply affiliation or endorsement. All trademarks used herein are the property of their respective owners.
View original content to download multimedia:https://www.prnewswire.com/news-releases/finngen-selects-azenta-to-propel-personalized-medicine-for-population-health-study-302203113.html
SOURCE Azenta
FAQ
What is Azenta's role in the FinnGen project?
How many participants are involved in the FinnGen study?
What technology will Azenta use for proteomics profiling in the FinnGen project?
What are the potential benefits of integrating proteomics data in the FinnGen project?
